Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

Worldwide, tuberculosis (TB) remains one of the top 10 causes of death, killing around 1.4 million people per year. An effective vaccine for TB is one of the primary goals of the VALIDATE Network, an international research network aiming to accelerate vaccine development for complex intracellular pathogens that are often neglected. The VALIDATE Network’s TB vaccine work has now received a $1.5 million funding boost from the Gates Foundation.

The money will support fellowships, grants and training for VALIDATE Network TB researchers, particularly female researchers, early-career researchers and researchers in low- and middle-income countries. By supporting these researchers to continue their work, the Gates Foundation hopes to accelerate the development of a robust pipeline of next-generation TB vaccine candidates, as well as boost the career development of the young TB scientists who do this vital work.

The VALIDATE Network, led by Professor Helen McShane from the University of Oxford, Professor Helen Fletcher from the London School of Hygiene and Tropical Medicine and Professor Samantha Sampson from the University of Stellenbosch, has always prioritised career development for its members alongside the scientific aims of vaccine development.

With around 450 members in 68 countries, the global network is an engaged and interactive community, offering both scientific opportunity and career support for its members, particularly in low- and middle-income countries. By encouraging cross-pathogen, cross-continent, cross-discipline and cross-species collaborations alongside supporting member’s development, the Network hopes to generate new ideas, share information and ultimately develop effective vaccines more quickly and easily in the future.

The new Gates Foundation funding will also enhance collaboration with the CTVD (Collaboration for TB Vaccine Discovery), an international network of scientists dedicated to fostering innovation, cooperation, and collaboration in the TB vaccine space, opening up further opportunities for learning, training and discovery.

Professor Helen McShane, Professor of Vaccinology at the University of Oxford and Director of VALIDATE, says, ‘We are delighted that the Gates Foundation has recognised the value of the VALIDATE Network that we have established, both scientifically and to support career development. We look forward to working with the Foundation to continue to support career development, with a shared focus particularly on women and low- and middle-income setting researchers.’

Professor Samantha Sampson, Principal Investigator in Mycobacteriology at the Division of Molecular Biology and Human Genetics, University of Stellenbosch in South Africa and Co-Director on the Gates Foundation funding, says, ‘I am very excited about this opportunity to take a more active role in the VALIDATE Network. I am also very grateful for the support from the Gates Foundation, which will allow us to build on the already-strong network to further TB vaccine development through supporting research, collaboration and capacity development.’

While the current Gates Foundation funding focuses on the VALIDATE Network’s TB vaccine work, the Network is working on vaccine candidates for a range of intracellular neglected pathogens, including leishmaniasis, melioidosis and leprosy. These debilitating and deadly diseases are often forgotten, despite the widespread suffering they cause around the world, particularly in low-income countries and for those in poverty. The VALIDATE Network plans to secure matching funding from other sources for their other research priorities in the future.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.